After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Comparable sales in Q4 rose 13% year over year at Sephora at Kohl’s, which sees an “opportunity to strengthen cross-shopping ...

Discover Ulta Beauty's Q4 2024 highlights: new growth strategies, Ulta Beauty Unleash roadmap, & fiscal 2025 outlook.

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q4 2024 Earnings Call Transcript March 6, 2025 Atea Pharmaceuticals, Inc. misses on ...

“This is well above the 700-900 (prescriptions) we were hearing for buyside [analyst] expectations,” analysts at Evercore ISI ... wake of the fourth-quarter presentation, BridgeBio’s share ...

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) Q4 2024 Earnings Call Transcript March 4, 2025 Amylyx Pharmaceuticals, Inc.

Piper Sandler 36th Annual Healthcare Conference: Presentation Tuesday, December 3, 2024 at 8:00 am ET7th Annual Evercore HealthCONx Conference: Presentation Thursday, December 5, 2024 at 12:30 pm ...

The year’s margin expansion was indeed probably thanks to a higher Sephora mix, according to Evercore ISI analysts led by Michael Binetti. Those analysts also see that accentuating Kohl’s poor ...

President Trump’s economic policies are forcing other countries to wean themselves from a dependence on exports. U.S.

Ratings for Evercore (NYSE:EVR) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their ...